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Background: Transplant renal artery stenosis (TRAS) is an important cause of hypertension 
and renal allograft dysfunction occurring in kidney transplant recipients. However, conflicting 
predisposing risk factors for TRAS have been reported in the literature.
Objective: The aim of the present study was to assess the potential correlation between   possible 
risk factors and TRAS in a group of living donor renal transplant recipients 1 year after the 
renal transplantation.
Methods: We evaluated the presence of renal artery stenosis in 16 recipients who presented 
with refractory hypertension and/or allograft dysfunction 1 year after renal transplantation. 
  Screening for TRAS was made by magnetic resonance angiography and diagnosis was confirmed 
by conventional renal angiography. Age, gender, history of acute rejection, plasma lipid profile, 
serum creatinine, blood urea nitrogen, serum uric acid, calcium phosphate (CaPO4) product, 
alkaline phosphatase, fasting blood sugar, hemoglobin, and albumin were compared between 
the TRAS and non-TRAS groups.
Results: Of 16 kidney transplant recipients, TRAS was diagnosed in three patients (two men 
and one woman). High levels of calcium, phosphorous, CaPO4 product, and low-density lipo-
protein (LDL) cholesterol were significantly correlated with the risk of TRAS 1 year after renal 
transplantation (P , 0.05). Serum level of uric acid tended to have a significant correlation 
(P = 0.051).
Conclusion: Correlation between high CaPO4 product, LDL cholesterol, and perhaps uric acid 
and TRAS in living donor renal transplant recipients 1 year after renal transplantation might 
suggest the importance of early detection and tight control of these potential risk factors.
Keywords: transplant renal artery stenosis, atherosclerosis, calcium phosphate product, low 
density lipoprotein, uric acid
Introduction
Morbidity and mortality in renal transplant recipients has been attributed mainly to 
cardiovascular events.1 Among these events, transplant renal artery stenosis (TRAS) 
is the most frequent vascular complication after renal transplant. TRAS usually occurs 
between 3 months and 2 years after renal transplant with an incidence of 1% to 23%.2–5 
The clinical features of TRAS include refractory hypertension, new-onset hypertension, 
allograft dysfunction, and presence of bruit over the graft.2 Although TRAS usually 
arises close to the surgical anastomosis, pre- or post-anastomotic stenosis may also 
occur.5 Different locations and timings of disease onset may reflect particular   etiologies.5 
An anastomotic stenosis is commonly related to trauma to the donor or recipient 
vessels during surgical manipulation and usually arises early after transplantation.2 Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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In contrast, conflicting results have been reported about 
the predisposing risk factors for TRAS occurring late after 
transplantation (after 3 months).6 The factors potentially 
giving rise to TRAS include graft   rejection, atherosclerotic 
factors,7,8 cytomegalovirus infection,4,6,8 delayed graft 
function,6 and long, cold ischemia time in recipients of 
cadaveric grafts.3 The aim of this study was to investigate 
the possible risk factors for TRAS among a group of 
renal transplant recipients who presented with refractory 
hypertension and/or allograft dysfunction 1 year after their 
transplants.
Materials and methods
In this study, we evaluated the presence of renal artery 
  stenosis in a group of living, unrelated, donor renal trans-
plant recipients who presented with refractory hypertension 
and/or allograft dysfunction 1 year after renal transplanta-
tion between December 2006 and December 2007. The 
ethics committee of the university approved this study. An 
informed written consent was obtained from the patients 
before the study. Refractory hypertension was defined as arte-
rial pressure greater than 140/90 mmHg despite two or more 
antihypertensive drugs or hypertension requiring multiple 
drugs not controlled by pre-transplant antihypertensive drug 
requirements.8 Allograft dysfunction was defined as .50% 
rise of serum creatinine from the baseline. Screening for renal 
artery stenosis was made by magnetic resonance angiography 
(MRA) and diagnosis was confirmed by conventional renal 
angiography. Narrowing greater than 50% of the luminal 
diameter of the artery was considered hemodynamically 
significant.9 Age, gender, history of acute rejection, plasma 
lipid panels, serum creatinine, blood urea nitrogen, serum 
uric acid, calcium phosphate (CaPO4) product, alkaline phos-
phatase, fasting blood sugar, hemoglobin, and albumin were 
recorded for each patient. Exclusion criteria were patients 
with elevated cyclosporine level at presentation and patients 
with urologic problems at primary hospital   evaluation. 
  Maintenance immunosuppressant regimen included 
cyclosporine, mycophenolate mofetil, and corticosteroids in 
all patients. Patients with low-density lipoprotein (LDL) cho-
lesterol and uric acid levels of .100 mg/dL and .8 mg/dL 
received simvastatin and allopurinol,   respectively. All the 
studied patients, regardless of serum calcium level, were on 
calcitriol therapy (0.25 µg, daily).
Data are presented as mean ± standard deviation or as 
median and interquartile range. Statistical analysis was 
performed with SPSS (v 16; IBM Corp, Armonk, NY) using 
  Mann–Whitney U test and Fisher’s exact test, whenever 
appropriate. A P value , 0.05 was considered statistically 
significant.
Results
Sixteen kidney transplant recipients, seven men and nine 
women, were qualified for this study and underwent MRA 
(Table 1). Renal function deterioration in twelve patients 
(75%) and refractory hypertension in four patients (25%) 
led to clinical suspicion of TRAS. Three of four patients 
with   features of renal artery stenosis on MRA were con-
firmed to have TRAS by conventional angiography (18.7%, 
Table 1). With an estimation of total number of 700 kid-
ney transplantations in our center, incidence of late-onset 
TRAS was estimated as ∼0.4%. Two of the three patients 
with TRAS had stenosis on the anastomotic site (patients 2 
and 3), which showed improvement in symptoms after 
renal artery percutaneous transluminal angioplasty (PTA). 
Due to diffuse stenosis in a female patient (patient 1), no 
interventional procedures were performed to correct the 
stenosis. Raw data on patients with TRAS are shown in 
Table 2.
High levels of calcium (P = 0.03), phosphorus 
(P = 0.04), CaPO4 product (P = 0.02), and LDL cholesterol 
(P = 0.04) were significantly correlated with the risk of 
TRAS 1 year after renal transplantation. Serum level of uric 
acid tended to have a significant correlation (P = 0.051) 
Table 1 Patients’ baseline characteristics
Total (n = 16) TRAS (n = 3)
gender (male:female) 7:9 2:1
Age (year) 40.3 ± 14.2 41.0 ± 3.0
cause of EsRD
  cTin 4 (25%) 0 (0%)
  gn 4 (25%) 2 (66.6%)
  HTn 5 (31.2%) 0 (0%)
  Unknown 3 (18.7%) 1 (33.3%)
Admission cause
  Refractory HTn 4 (25%) 2 (66.6%)
  creatinine rise 12 (75%) 1 (33.3%)
Duration of hemodialysis  
prior to transplantation  
(months)
10 (6–19) 7 (6–48)
Time after transplantation  
(months)
36 (14.5–57) 48 (36–48)
systolic BP (mmHg) 130 (121.25–147.5) 150 (120–160)
Diastolic BP (mmHg) 80 (80–87.5) 90 (80–90)
Abbreviations:  TRAs,  transplant  renal  artery  stenosis;  EsRD,  end  stage  renal 
disease; cTin, chronic tubulointerstitial nephritis; gn, glomerulonephritis; HTn, 
hypertension; BP, blood pressure; n, number.Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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Table 2 Data on patients with transplant renal artery stenosis 
(TRAs) (n = 3)
Variable Patient 1 Patient 2 Patient 3
Age (year) 38 41 44
gender Female Male Male
History of acute rejection Yes no no
cause of EsRD Unknown gn gn
Admission cause creatinine  
rise
Refractory  
HTn
Refractory   
HTn
Duration of hemodialysis  
before transplantation  
(months)
48 6 7
Time after transplantation 
(months)
48 48 36
systolic BP (mmHg) 120 160 150
Diastolic BP (mmHg) 80 90 90
creatinine (mg/dL) 6 2.1 1.7
BUn (mg/dL) 99 42 40
Hemoglobin (g/dL) 14 10.5 10
LDL (mg/dL) 150 116 104
Triglyceride (mg/dL) 216 181 181
cholesterol (mg/dL) 177 200 200
Uric acid (mg/dL) 10 8 8.5
Albumin (g/dL) 3.4 4.3 4
HDL (mg/dL) 16 48 48
Alkaline phosphatase (U/L) 200 174 180
FBs (mg/dL) 96 100 95
calcium (mg/dL) 9.5 9.7 10
Phosphorus (mg/dL) 5 4.6 5
caPO4 product (mg2/dL2) 47.5 44.6 50
Abbreviations:  EsRD,  end  stage  renal  disease; gn,  glomerulonephritis;  HTn, 
hypertension; BP, blood pressure; BUn, blood urea nitrogen; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; FBs, fasting blood sugar.
Table 3 Univariate analysis of recipient variables for transplant 
renal artery stenosis (TRAs)
Variable Non–TRAS  
group (n = 13)
TRAS  
group (n = 3)
P value
Age (year) 43 (23.5–52.5) 41 (38–44) 0.94a
gender (male:female) 5:8 2:1 0.55b
Positive history  
of acute rejection
2 (15.4%) 1 (33.3%) 0.48b
simvastatin intake 5 (38.4%) 3 (100%) 0.20b
Allopurinol intake 3 (23%) 3 (100%) 0.03b*
creatinine (mg/dL) 1.7 (1.5–2.1) 2.1 (1.7–6) 0.19a
BUn (mg/dL) 36 (31–52) 42 (40–99) 0.20a
Hemoglobin (g/dL) 10 (9.4–10.1) 10.5 (10–14) 0.08a
LDL (mg/dL) 78 (72–102) 116 (104–150) 0.04a*
Triglyceride (mg/dL) 136 (100.5–188.5) 181 (181–216) 0.31a
cholesterol (mg/dL) 157 (134–170) 200 (177–200) 0.06a
Uric acid (mg/dL) 6.5 (4.8–7.5) 8.5 (8–10) 0.05a
Albumin (g/dL) 4 (3.7–4.3) 4 (3.4–4.3) 0.89a
HDL (mg/dL) 45 (35–50.5) 48 (16–48) 0.73a
Alkaline phosphatase  
(U/L)
190 (134–298) 180 (174–200) 0.94a
FBs (mg/dL) 100 (87.5–150) 96 (95–100) 0.63a
calcium (mg/dL) 9 (8.9–9.2) 9.7 (9.5–10) 0.03a*
Phosphorus (mg/dL) 4 (3.1–4.6) 5 (4.6–5) 0.04a*
caPO4 product  
(mg2/dL2)
36 (28.4–42.3) 47.5 (44.6–50) 0.02a*
Notes: *Statistically significant (P , 0.05); aMann–Whitney U test; bFisher’s exact test. 
Abbreviations: BUn, blood urea nitrogen; LDL, low-density lipoprotein; HDL, 
high-density lipoprotein; FBs, fasting blood sugar.
(Table 3). There were no differences in other risk factors 
for atherosclerosis including hypertension and obesity 
(BMI $ 30 kg/m2) between the patients with and without 
TRAS (P . 0.05). None of the patients had diabetes mel-
litus before the renal transplant. However, four patients in 
the non-TRAS group had post-transplant diabetes mellitus 
(P . 0.05).
Discussion
TRAS is the most frequent vascular complication in renal 
transplantation.2 TRAS can occur due to multiple eti-
ologies, but stenosis occurring later after transplantation 
usually reflects atherosclerotic disease.8,10 In this study, 
we focused on potential risk factors of TRAS. The study 
revealed that CaPO4 product, LDL cholesterol, and perhaps 
uric acid may increase the risk of TRAS development late 
after renal transplantation. The former, although not inves-
tigated in TRAS, has been correlated with an increased 
risk for allograft loss in kidney transplant recipients as 
described by Schaeffner et al.11 Interestingly, in a study on 
apolipoprotein E-deficient mice with normal and reduced 
renal function, Phan and colleagues found that the pro-
gression of intimal and medial arterial calcification was 
reduced after the administration of sevelamer (phosphate 
binder) with a significant decrease in the serum phosphate 
and calcium product while the serum total cholesterol 
remained unchanged.12 Research has also shown that in 
chronic hemodialysis patients, with no clinical evidence 
of infectious or inflammatory conditions, CaPO4 prod-
uct was directly related to the C-reactive protein (CRP) 
  concentrations.13 An elevated plasma concentration of 
CRP, in turn, is generally believed to be an indicator of car-
diovascular risk both in non-uremic and uremic patients.14 
We propose that an elevated calcium phosphate product 
may mean that renal transplant patients are susceptible to 
TRAS, possibly by induction of inflammation, vascular 
calcification, and accelerated atherosclerosis. Evidence 
suggests that the goal level of CaPO4 product should be 
below 55 mg2/dL2. In other words, there is increased risk 
for development of calcification and possibly increased 
risk for lower patient survival if CaPO4 product levels Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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exceed 55 mg2/dL2.15 In the present study, although the 
median CaPO4 product was lower than the recommended 
level (47.5 vs 55 mg2/dL2), high CaPO4 product level 
was correlated with late-onset TRAS. Therefore, related 
guidelines should be updated in this regard to define a 
more appropriate goal level of CaPO4 product in the renal 
transplant population.
High levels of LDL were also significantly associated 
with TRAS in our study. Although Scoble et al found no 
significant difference in LDL levels between non-transplant 
patients with atherosclerotic renal artery stenosis, and 
controls,16 Ruiz et al found that LDL was higher in stable 
renal transplant patients with atherosclerotic carotid artery 
lesions, than in patients without carotid lesions.17 Notably, 
it has been shown that renal transplant recipients had lower 
activity of serum paraoxanase, which inhibits oxidation of 
LDL.18 On the other hand, it has been shown that increased 
oxidative stress and final products of lipid peroxidation 
along with reduced antioxidant status might be observed in 
patients after renal transplantation, compared with healthy 
individuals.17,19 Hence, it is quite possible that LDL in set-
ting of decreased antioxidant activity may contribute to 
the accelerated atherosclerosis in renal transplant patients. 
Nonetheless, the present study did not address the issue of 
antioxidant capacity among renal transplant patients. The 
indicated reduced antioxidant capacity in renal transplant 
patients may provide an environment in which uric acid acts 
as pro-oxidant contributing to the accelerated atherosclerosis 
through inducing endothelial dysfunction and inflammation.20 
Although uric acid in the early stages of the atherosclerotic 
process is known to act as an antioxidant, it is pro-oxidative 
under reduced antioxidant status, as well.19 This might rein-
force the importance of a high level of uric acid as a probable 
risk factor of TRAS, though this parameter merely tended to 
correlate with TRAS in the present study.
This study has certain limitations. It was a single-center 
study with quite a small sample size. Evaluation of the risk 
factors for renal artery stenosis in kidney transplants is 
recommended in larger, possibly multi-center populations. 
The TRAS group comprised only three patients and thus the 
statistical analysis of data may not be applicable. Therefore, 
the raw data of each case were also included.
In conclusion, it seems that high CaPO4 product, LDL 
cholesterol, and perhaps uric acid are correlated with TRAS 
in living donor renal transplant recipients 1 year after the 
renal transplantation, suggesting the importance of early 
detection and tight control of these potential risk factors. 
Further prospective studies are needed to define the risk 
factors of TRAS.
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